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scute Coronary Syndromes:
o CRP or Not to CRP?
e read with interest the article by Bogaty et al. (1), in which the
uthors failed to find an independent association between
-reactive protein (CRP) and outcome in a large, unselected
opulation of patients presenting an acute coronary syndrome
ACS). We agree with the authors that their results do not support
linical use of CRP in patients hospitalized with an ACS. It should
e made crystal clear, however, that this study does not challenge
he notion that activation of inflammatory cells and mediators
lays a key role in the pathogenesis of coronary instability and that
he design of the study may explain the difference between plenty
f data demonstrating the role of CRP in acute coronary syn-
romes (2). Indeed, the wide inclusion criteria adopted in this
tudy inevitably mask the ability of a sensitive but nonspecific
arker like CRP to reveal the underlying pathogenetic role of
nflammation. For instance, Bogaty et al. (1) included the whole
pectrum of ACS from Braunwald’s class IB unstable angina to
T-segment elevation myocardial infarction. At one extreme,
mong patients without myocardial necrosis or with a mild
levation of troponins (as it is the case in a sizeable proportion of
atients without ST-segment elevation ACS), an elevated CRP
evel, in the absence of systemic inflammatory diseases, is likely to
eflect widespread activation of inflammatory cells and is, there-
ore, a marker of coronary disease activity. Accordingly, several
revious studies have shown that in this setting CRP levels predict
he risk of recurrent instability independently of troponin levels
2). At the other extreme among patients with ST-segment
levation myocardial infarction, CRP predominantly reflects the
nflammatory response to myocardial necrosis; in this setting the
redictive value of CRP is obviously related to measures of
yocardial damage including cardiac enzyme levels and indexes of
eft ventricular dysfunction, although the association is far from
inear and is influenced by the previous inflammatory condition
3). Furthermore, the authors did not exclude patients with acute
r chronic inflammatory diseases, which can further confound the
nterpretation of the results from the study.
Finally, the statistical analysis may underestimate the predictive
alue of CRP. Indeed, in the logistic regression analysis, contin-
ous levels of CRP were compared with dichotomous variables,
hus reducing their ability to compete with the other variables. A
urther analysis was conducted to establish the predictive value of
RP levels, using a cutoff of 3 mg/l. Although this cutoff was
tilized in previous studies on CRP in ACS, a scientific statement
f the Centers for Disease Control and Prevention/American
eart Association proposed a cutoff of 10 mg/l as more appropri-
te when the predictive value of CRP is assessed in ACS (4).
Finally, the study does not provide any insight into the
echanisms responsible for the association between CRP levels
nd death, which has been found in this and in previous studies. In
articular, why are higher levels of CRP consistently associated tith a higher risk of death? What kind of cardiac deaths do these
atients die? This association might be accounted for by: 1) a
igher risk of recurrent instability with fatal infarctions if CRP is
marker of plaque inflammation; 2) a higher risk of sudden death
f CRP is a marker of an arrhythmogenic substrate; and 3) a higher
isk of early post-infarction complication if CRP plays a pathoge-
etic role in determining infarct size related to complement
ctivation in the infarcted tissue.
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eply
e appreciate the interest expressed by Dr. Biasucci and col-
eagues in our work (1). We prospectively found, in 1,210 patients
epresenting a broad spectrum of acute coronary syndromes, that
he inflammatory marker C-reactive protein (CRP), whether
easured on admission, at hospital discharge, or 30 days later, did
ot have incremental clinical utility to predict the occurrence of
eath, myocardial infarction, or unstable angina (UA) with elec-
rocardiogram changes at 1 year (primary end point) (1). Dr.
iasucci and colleagues argue that our inclusion of patients with
ignificant acute myocardial necrosis (about two-thirds), in itself a
timulator of CRP release, and those with concomitant inflamma-
ory conditions confounds the predictive ability of CRP. We
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October 28, 2008:1500–1elieve this points precisely to the major limitation of using a
onspecific marker like CRP for coronary risk prediction. Simi-
arly, why not also exclude patients with other possible confound-
rs like obesity, depression, fatigue, diet, medications, and so on?
ho would ultimately remain to be tested with CRP in clinical
ractice? Indeed, is it not questionable to exclude patients with
nflammatory conditions when background (nonspecific) inflam-
ation as reflected by raised CRP might increase coronary risk in
hese patients (2)?
Nonetheless, we report here the predictive ability of CRP in our
tudy when the analysis is restricted to the 461 UA patients
ithout significant myocardial damage. The odds ratio (OR) and
5% confidence intervals (CIs) for admission CRP to predict the
rimary end point at 1 year was 1.21 (95% CI: 0.97 to 1.51; p 
.1) and adjusted it was 1.07 (95% CI: 0.85 to 1.36; p  0.6). The
R of CRP measured at hospital discharge was 1.03 (95% CI:
.83 to 1.28; p  0.8) and adjusted OR was 0.99 (95% CI: 0.79 to
.25; p  1.0). The OR of CRP measured 30 days later was 1.16
95% CI: 0.88 to 1.52; p  0.3) and adjusted OR was 1.10 (95%
I: 0.83 to 1.47; p  0.5). Findings were unchanged when the
nalysis was restricted to the 326 UA patients with negative
roponin levels. Finally, results were unchanged when patients with
oncomitant inflammatory conditions (about 25%) were excluded.
Dr. Biasucci and colleagues suggest using a CRP cutoff of 10
g/l instead of analyses with continuous values. Besides the
otential loss of information with this approach, such a cutoff is
uite arbitrary. The scientific statement of the Centers for Disease
ontrol and Prevention/American Heart Association only specu-
ated on use of this value without supporting references and did not
ctually recommend it (3). Nevertheless, we redid all of the
reviously mentioned analyses using the 10 mg/l cutoff and found
t to have no clinical utility.
Finally, Dr. Biasucci and colleagues critique our study for not
roviding pathogenetic insight into the relation between CRP and
isk of death. Our study was designed as a clinical, not mechanistic,
tudy. The univariate link we found between CRP and death
issolved in multivariate analyses. Our study supports the notionhat clinicians do not need CRP to know who are the sicker
atients who are more likely to die as well as to have raised
nflammatory markers (4). While we appreciate the pathogenetic
mportance of inflammation in acute coronary disease, this is insuffi-
ient to establish a seamless link to clinical use of an inflammatory
arker for risk prediction. To CRP or not to CRP? For risk
rediction in our study, CRP appears to be “dead, for a ducat, dead”
the Bard gratefully acknowledged).
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